-
The untold impact of childhood bedwetting in later life
in Uncategorized amNew data, presented today at the International Continence Society (ICS) congress in Glasgow1, suggest that bedwetting…
-
New research reveals night-time toilet trips are not a trivial problem
in Uncategorized amNew data, presented at the International Continence Society (ICS) Congress, highlight the significant detrimental impact of nocturia…
-
New data demonstrating long-term benefits of FIRMAGON® (degarelix) for advanced hormone-dependant prostate cancer published in The Journal of Urology
in Uncategorized amNew data, published in the September issue of The Journal of Urology, showed that long-term use of FIRMAGON®…
-
MEGASET Study demonstrated effectiveness and tolerability of MENOPUR® after ICSI in GnRH antagonist cycles
in Uncategorized amNew data1, presented today at the European Society of Human Reproduction and Embryology (ESHRE) meeting, demonstrated the efficacy…
-
Ongoing extension study results provide further evidence for first-line use of FIRMAGON® (degarelix) in advanced prostate cancer
in Uncategorized amRecent data from the ongoing five-year FIRMAGON® (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability of…
-
SMC Announces Acceptance of Degarelix (FIRMAGON®▼) for use within NHS Scotland
in Uncategorized amToday’s decision by the Scottish Medicines Consortium (SMC) (www.scottishmedicines.org.uk) to accept the use of FIRMAGON…
-
Ferring celebrated its 60th anniversary
in Uncategorized amFerring was founded in 1950 and celebrated its 60th anniversary in 2010. The company has evolved from a small 2-people…
0 -
Extension study with FIRMAGON® (degarelix) showed continued benefits for prostate cancer patients beyond one year
in Uncategorized amData recently presented on FIRMAGON® (degarelix) hormonal therapy for prostate cancer showed that long-term use beyond one year…
-
Ferring acquires LYSTEDA™ from Xanodyne Pharmaceuticals, Inc.
in Uncategorized amFerring Pharmaceuticals today announced an agreement that will expand its Women’s Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical’s LYSTEDA™…
-
Consider the “whole-man” when treating prostate cancer
in Uncategorized amHealthcare professionals need to consider the impact of prostate cancer on the ‘whole man’ rather than focusing on cancer treatment in isolation, according to results from an international survey of prostate cancer patients and their partners…
Uncategorized
Uncategorized
